[1] |
GUO Ningzi, LIU Li, YUE Ruiqi, FENG Huiqing, YANG Huaxin, WEI Ningyi, CHEN Hua.
Determination of particle size distribution of chiglitazar sodium by laser diffraction method
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 147-151.
|
[2] |
XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue.
285 cases of adverse drug reaction related to new antineoplastic drugs
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203.
|
[3] |
FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan.
One case of generalized myalgia caused by oxaliplatin
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210.
|
[4] |
LI Na, GUO Jun, GUO Wenjia, LYU Yinyin, LI Caihong, MU Xiangdong.
One case of delayed skin allergic reaction caused by asthma treated with omalizumab injection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 211-212.
|
[5] |
ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie.
Adverse reaction monitoring of toothpaste in China under the new regulatory system
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222.
|
[6] |
YUE Lanxin, SHEN Pan, ZHOU Lei, HUANG Congshu, ZHOU Wei, GAO Yue.
The inhibitory effect and mechanism of Celastrol on adipogenic differentiation in 3T3-L1
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 65-73.
|
[7] |
BUCHANAN James.
Assessment of drug-induced liver injury via nR modified Hy’s law and PALT
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 117-120.
|
[8] |
LIU Qian, HU Jing, LI Bo, YANG Xiaojing.
Jinghuaweikang capsules combined with quadruple therapy in the treatment of Helicobacter pylori associated gastritis: a systematic evaluation and meta-analysis
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1039-1045.
|
[9] |
YANG Minghan, QIAO Meiling, LUO Jiaoyang, YANG Meihua, SHENG Ping.
Acute toxicity of anti-gastric cancer active ingredients of Ferula ferulaeoides
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 880-884.
|
[10] |
HE Xiong, MA Junlong, YANG Guoping.
Adverse events caused by HER2 conjugated antibodies via FAERS
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 915-920.
|
[11] |
MA Qihong, SHI Yuanyuan, CHEN Fangfang, WU Kang, BU Zixuan, LU Tiangong.
Mechanisms of celastrol for ovarian cancer: based on quantitative proteomics
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 721-727.
|
[12] |
YAN Yishu, ZHAO Yan, LU Tiangong, SUN Zhenxiao.
Emodin -8-O-β-D-glucoside combined with paclitaxel inhibits the viability and metastasis of human breast cancer cells
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 728-734.
|
[13] |
SHEN Ningning, LIU Yufu, RU Yi, SHI Zhuo, YANG Chunqi, NI Zhexin, XIAO Chengrong, MA Zengchun, WANG Yuguang, GAO Yue.
Antifatigue effect of ophiopogonin D on exhaustive swimming in mice
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 749-753.
|
[14] |
WANG Rong, LIU Ziqun, WANG Nana, TAN Xiong, ZHANG Yixin, YANG Kuan, QIN Bei.
Acute toxicity of proline Danshensu borneol ester in mice
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 754-757.
|
[15] |
SU Yuefen, ZHENG Jingrou, GONG He, XIE Guangtong, ZHANG Jie, SAI Chunmei.
Formability and mechanism of breast nodule pain-alleviating gel plaster for the treatment of breast hyperplasia
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 783-790.
|